BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

19 related articles for article (PubMed ID: 38639528)

  • 1. In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene.
    Kamal MM; Mia MS; Faruque MO; Rabby MG; Islam MN; Talukder MEK; Wani TA; Rahman MA; Hasan MM
    Sci Rep; 2024 May; 14(1):11607. PubMed ID: 38773180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylation-dependent MCM6 repression induced by LINC00472 inhibits triple-negative breast cancer metastasis by disturbing the MEK/ERK signaling pathway.
    Shao G; Fan X; Zhang P; Liu X; Huang L; Ji S
    Aging (Albany NY); 2021 Feb; 13(4):4962-4975. PubMed ID: 33668040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MCM6 promotes intrahepatic cholangiocarcinoma progression by upregulating E2F1 and enhancing epithelial-mesenchymal transition.
    Gao C; Li J; Zeng F; Wang L; Chen K; Chen D; Hong J; Qu C
    Carcinogenesis; 2023 Jun; 44(4):279-290. PubMed ID: 37185675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
    Liu M; Hu Q; Tu M; Wang X; Yang Z; Yang G; Luo R
    J Exp Clin Cancer Res; 2018 Jan; 37(1):10. PubMed ID: 29357919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minichromosome maintenance 6 complex component identified by bioinformatics analysis and experimental validation in esophageal squamous cell carcinoma.
    Li X; Ren Z; Xiong C; Geng J; Li Y; Liu C; Ren C; Liu H
    Oncol Rep; 2020 Sep; 44(3):987-1002. PubMed ID: 32583000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High MCM6 expression promotes proliferation and correlates with poor prognosis in triple-negative breast cancer.
    Zhang H; Lin YD; Zhuang MX; Zhu L; Yu Y; Chen XG; Wang QS; Lin MB
    Eur Rev Med Pharmacol Sci; 2024 Apr; 28(7):2906-2922. PubMed ID: 38639528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression.
    Liu Z; Li J; Chen J; Shan Q; Dai H; Xie H; Zhou L; Xu X; Zheng S
    BMC Cancer; 2018 Feb; 18(1):200. PubMed ID: 29463213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The DNA replication regulator MCM6: An emerging cancer biomarker and target.
    Zeng T; Guan Y; Li YK; Wu Q; Tang XJ; Zeng X; Ling H; Zou J
    Clin Chim Acta; 2021 Jun; 517():92-98. PubMed ID: 33609557
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.